Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Morphic Therapeutic
MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1Q22 Announced appointment of Nisha Nanda, Ph.D.,...
Morphic to Participate in Jefferies IBD Therapeutics Summit
October 12, 2021 16:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Participation in September Investor Conferences
September 01, 2021 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors
August 23, 2021 16:01 ET
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Second Quarter 2021 Financial Results
August 04, 2021 07:00 ET
|
Morphic Therapeutic
MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program expected to begin 1Q22 Presented positive preclinical data from αvβ8 program at AACR...
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
July 09, 2021 06:35 ET
|
Morphic Therapeutic
MORF-057 well tolerated across all phase 1 cohorts Dose-dependent α4β7 receptor occupancy (RO) observed with receptor saturation at 100 mg dose Biomarker changes including lymphocyte subset...
Morphic Therapeutic to Host Analyst and Investor Call on July 9, 2021
July 02, 2021 09:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO’21 Virtual Congress
May 28, 2021 08:00 ET
|
Morphic Therapeutic
Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens...
Morphic Therapeutic to Present at the Jefferies Virtual Healthcare Conference
May 28, 2021 07:30 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and First Quarter 2021 Financial Results
April 29, 2021 08:00 ET
|
Morphic Therapeutic
Expanded research and development collaboration with Janssen for third integrin program Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 Received acceptance to...